# The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

> **NCT03097120** · PHASE3 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 309 (actual)

## Conditions studied

- Heart Disease

## Interventions

- **DRUG:** 0.625 mg of conjugated equine estrogen
- **DRUG:** 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
- **DRUG:** placebo tablets

## Key facts

- **NCT ID:** NCT03097120
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-01
- **Primary completion:** 2001-01
- **Final completion:** 2001-01
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2023-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03097120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03097120, "The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03097120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*